March 01, 2015 8:48 PM ET

Company Overview of ALS Therapy Development Institute

Company Overview

215 1st Street

Suite 238

Cambridge, MA 02142-1236

United States

Key Executives for ALS Therapy Development Institute

Chief Executive Officer and Chief Scientific Officer
Founder and Director
Director of Communications & Public Affairs
Compensation as of Fiscal Year 2014.

ALS Therapy Development Institute Key Developments

ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments for ALS

ALS Therapy Development Institute together with its wholly-owned subsidiary, Anelixis Therapeutics, announced that it has formed a research partnership with Neurimmune to advance potential treatments for ALS, also known as Lou Gehrig's disease. The research partnership will explore a human monoclonal antibody that targets misfolded superoxide dismutase 1 (SOD1). Misfolded SOD1 accumulates in familial and sporadic ALS, suggesting a generalized role as a drug target for ALS treatments. The collaboration will explore the high-affinity human antibodies developed by Neurimmune that selectively target misfolded SOD1. In preclinical studies with transgenic mice, chronic antibody treatment significantly reduced SOD1 pathology and rescued spinal cord motor neurons, resulting in significantly reduced muscle atrophy, better motor functions and increased survival.

The ALS Therapy Development Institute Appoints Jennifer 'Jenny' Gore Dwyer of Kenmore to its Board of Directors

The ALS Therapy Development Institute (ALS TDI) announced that it has elected Jennifer 'Jenny' Gore Dwyer of Kenmore, WA, to its Board of Directors. Dwyer is part of a wave of additions to the board this year, as ALS TDI looks to grow and accelerate its drug development and venture philanthropy programs designed to end ALS. The Institute's board has grown to include 15 members with deep ties to the ALS community and vast experience in leadership positions across multiple industries.

ALS Therapy Development Institute Adds Two Board Members

The ALS Therapy Development Institute announced that it has added two members to its board of directors: Robert Sepucha Jr. and Michael M. Smith. The Institute's board grows to include 14 members with deep ties to the ALS community, academic research, philanthropy and pharmaceutical development. Robert Sepucha Jr. is senior vice president, policy and business development for Fresenius Medical Care North America. Prior to joining Fresenius, Sepucha served as general counsel for the Massachusetts Life Science Center, as well as chief of staff and senior policy advisor to Congressman Harold Ford Jr. (D-TN), where he was the Congressman's primary advisor on legislative strategy, political activities, media strategy and legal issues. Michael M. Smith is president of B.T. Loftus Ranches Inc. He is also founder, director and former president of Yakima Chief Inc., an international hops sales organization.

Similar Private Companies By Industry

Company Name Region
Cutler & Co., LLC United States
Prime Time Companies, LLC United States
ABC, Inc. United States
Energia United Trading and Procurement Company LLC United States
NuORDER Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALS Therapy Development Institute, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at